SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance

SciSparc (Nasdaq: SPRC) received a Nasdaq notification that it is not in compliance with the minimum stockholders’ equity requirement under Rule 5550(b)(1), which requires at least $2,500,000 in equity.

Rhea-AI Summary

SciSparc (Nasdaq: SPRC) received a Nasdaq notification that it is not in compliance with the minimum stockholders’ equity requirement under Rule 5550(b)(1), which requires at least $2,500,000 in equity. The company reported approximately $(81,000) in stockholders’ equity as of June 30, 2025. SciSparc has 45 calendar days (until February 26, 2026) to submit a plan to regain compliance; if accepted Nasdaq may grant up to a 180-day extension to evidence compliance. The notice has no immediate effect on listing and shares will continue trading as SPRC. The company expects to demonstrate compliance as of December 31, 2025 following proceeds from an $4.2 million debenture conversion in August 2025 and its November 2025 registered direct offering.

Positive

• Company expects to demonstrate compliance as of Dec 31, 2025
• Proceeds from $4.2M debenture conversion in August 2025
• Ordinary shares will continue trading on Nasdaq under SPRC during grace period

Negative

• Received Nasdaq notice for failing to meet $2,500,000 equity minimum
• Reported stockholders’ equity of $(81,000) as of June 30, 2025
• Must submit compliance plan by Feb 26, 2026 or face further action

Argus Jan 13 session

-15.52% close to close Open Argus

Details

News Market Reaction – SPRC

In the Jan 13 session, SPRC declined 15.52%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -15.5% in the session following this news. A negative reaction despite the company...

Analysis

The stock dropped -15.5% in the session following this news. A negative reaction despite the company’s stated plan fits a pattern where SciSparc news has often been followed by weakness. The Nasdaq notice underscores previously reported stockholders’ equity of $(81,000) versus the $2,500,000 requirement, raising balance sheet concerns. While management points to the $4.2 million debenture conversion and a November 2025 offering to regain compliance, investors may remain cautious given past post-news declines and ongoing capital structure uncertainty.

Key Figures

Nasdaq equity requirement: $2,500,000 stockholders’ equity Reported equity: $(81,000) stockholders’ equity Plan deadline: 45 calendar days +5 more

Nasdaq equity requirement

$2,500,000 stockholders’ equity

Minimum for Nasdaq Capital Market Listing Rule 5550(b)(1)

Reported equity

$(81,000) stockholders’ equity

As of June 30, 2025 per Form 6-K dated November 18, 2025

Plan deadline

45 calendar days

Time to submit compliance plan to Nasdaq; until February 26, 2026

Extension period

Up to 180 calendar days

Potential Nasdaq extension from date of notification letter

Debenture principal converted

$4.2 million

Principal amount of debentures dated February 25, 2025 converted in August 2025

Accrued interest converted

Accrued interest (amount not specified)

Converted alongside $4.2 million debenture principal in August 2025

Registered direct offering

Proceeds (amount not specified)

Company cites November 2025 registered direct offering proceeds as support for compliance

Compliance assessment date

December 31, 2025

Date by which company expects to demonstrate Nasdaq equity compliance

Historical Context

5 past events · Latest: Dec 30

5 events

1. Dec 30

   Patent grant

   24h Move

   -1.5%

   NeuroThera received an Israeli patent for opioid-based pain relief technology.

2. Dec 02

   Acquisition term sheet

   24h Move

   -4.9%

   NeuroThera signed non-binding term sheet to acquire majority in bio data firm.

3. Dec 01

   Device IP acquisition

   24h Move

   -16.4%

   SciSparc planned GERD device market entry via acquisition of MUSE system IP.

4. Nov 26

   Device IP acquisition

   24h Move

   -9.0%

   Signed term sheet to acquire patents and know-how for innovative endoscopy systems.

5. Nov 20

   Patent application

   24h Move

   -4.5%

   NeuroThera filed Israeli patent application for MEAI-based depression treatment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq capital market, listing rule 5550(b)(1), form 6-k, registered direct offering, +1 more

5 terms

nasdaq capital market regulatory

"continued listing on the Nasdaq Capital Market, listing Rule 5550(b)(1)"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

listing rule 5550(b)(1) regulatory

"non-compliance with the minimum stockholders’ equity requirement... Rule 5550(b)(1)"

Listing Rule 5550(b)(1) is a Nasdaq listing standard that sets a minimum share price requirement companies must meet to stay listed on the exchange. It matters to investors because falling below that threshold can trigger delisting procedures, which often reduce a stock’s visibility, trading liquidity and value; think of it like a minimum score needed to remain in a sports league — miss it and you risk being dropped until you improve.

form 6-k regulatory

"In the Company’s Form 6-K dated November 18, 2025, the Company reported"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

registered direct offering financial

"pursuant to the Company’s registered direct offering in November 2025."

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

debentures financial

"conversion in August 2025 of the principal amount of $4.2 million and accrued interest of debentures"

A debenture is a company’s long-term IOU sold to investors that promises regular interest payments and repayment of principal at a set date; unlike equity, it represents debt rather than ownership. Think of it like lending money to a business in exchange for a fixed stream of payments, so investors watch a debenture’s interest rate and the borrower’s financial health to judge income reliability and risk of not being repaid.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today that it has received a written notification (the “Notification Letter”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, listing Rule 5550(b)(1), due to its failure to maintain a minimum of $2,500,000 in stockholders’ equity. In the Company’s Form 6-K dated November 18, 2025, the Company reported stockholders’ equity of approximately $(81,000) as of June 30, 2025.

In accordance with Nasdaq rules, the Company has 45 calendar days, or until February 26, 2026, to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance. The Notification Letter has no immediate effect on the Company’s listing on the Nasdaq Capital Market, and during the grace period, as may be extended, the Company’s ordinary shares will continue to trade on Nasdaq under the symbol “SPRC”.

The Company expects that it will be able to demonstrate compliance with the Nasdaq stockholders’ equity requirement as of December 31, 2025 following the proceeds received from the conversion in August 2025 of the principal amount of $4.2 million and accrued interest of debentures dated February 25, 2025 and pursuant to the Company’s registered direct offering in November 2025.
  

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses regaining compliance with Nasdaq’s continued listing requirements, the timing and effect thereof. The acquisition of the intellectual property assets described in this press release is subject to customary closing conditions, including any required regulatory approvals. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq rule did SciSparc (SPRC) fail to meet on Jan 12, 2026?

SciSparc was notified of non-compliance with Nasdaq Capital Market Rule 5550(b)(1), the minimum stockholders’ equity requirement.

How much stockholders’ equity does Nasdaq require and how much did SPRC report?

Nasdaq requires $2,500,000 minimum; SciSparc reported approximately $(81,000) as of June 30, 2025.

What deadline does SciSparc have to submit a plan to regain compliance for SPRC?

The company has 45 calendar days, until February 26, 2026, to submit a plan to Nasdaq.

Will SPRC remain listed and tradable after the Nasdaq notice?

Yes. The Notification Letter has no immediate listing effect and ordinary shares will continue trading as SPRC during the grace period.

What actions does SciSparc cite to regain Nasdaq compliance for SPRC?

SciSparc expects to show compliance as of Dec 31, 2025 after proceeds from an $4.2M debenture conversion and its November 2025 registered direct offering.